Companies › CG Oncology
1 active drug program in 3 registered trials: 2 Phase 3, 1 Phase 2; Oncology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Cretostimogene Grenadenorepvec Engineered oncolytic adenovirus expressing GM-CSF | – | Phase 3 | Non Muscle Invasive Bladder Cancer; High-Risk Non-Muscle-Invasive Bladder Cancer | Nov 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06111235 | Cretostimogene Grenadenorepvec | Phase 3 | Non Muscle Invasive Bladder Cancer | Oncology | Nov 2026 |
| NCT06567743 | Cretostimogene Grenadenorepvec | Phase 2 | High-Risk Non-Muscle-Invasive Bladder Cancer | Oncology | Mar 2027 |
| NCT04452591 | Cretostimogene Grenadenorepvec | Phase 3 | Non Muscle Invasive Bladder Cancer | Oncology | Jun 2030 |
Cash and short-term investments of $984m on 2026-09-30; operating cash outflow about $203m a year; runway about 58 months at that burn, to Aug 2031; 3 of 3 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 8 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
No annotated target.
–
Suzhou Immunofoco Biotechnology Lakefront Biotherapeutics GT Medical Technologies Biofrontera Delcath Systems
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.